



## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/029,359 12/21/2001		12/21/2001	Anneli Attersand	10806-156 4324		
24256	7590	01/27/2003				
DINSMOF	RE & SHO	OHL, LLP	EXAMINER			
1900 CHEN			MAYES, LAURIE A			
255 EAST I						
CINCINNA	III, OH 2	13202		ART UNIT	PAPER NUMBER	
				1653		
				DATE MAILED: 01/27/2003	16	
					1 /	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application	No.		Applicant(s)					
•					ATTERSAND, ANNELI					
	Office Action Summary		10/029,359		Art Unit					
	Office Action Summary	Examiner								
		Laurie May			1653	dress				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply										
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status										
1)	Responsive to communication(s) filed on	·								
2a)□	•	This action is r	non-final.							
3)	Since this application is in condition for al closed in accordance with the practice un	llowance except nder <i>Ex parte Qu</i>	for forma	al matters, pro 35 C.D. 11, 45	secution as to this O.G. 213.	ne merits is				
Dispositi	on of Claims	,								
	Claim(s) 1-10 is/are pending in the application					-				
	4a) Of the above claim(s) is/are with	ndrawn from con	sideratio	n.						
5)	Claim(s) is/are allowed.									
<i>'</i> —	6) Claim(s) is/are rejected.									
	Claim(s) is/are objected to.									
	Claim(s) <u>1-10</u> are subject to restriction and	d/or election req	uirement.							
• •	on Papers  The appeignation is objected to by the Eval	miner								
9) The specification is objected to by the Examiner.										
10)	10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).									
11)	The proposed drawing correction filed on _	is: a)	oproved b	o) disapprov	ved by the Exami	ner.				
If approved, corrected drawings are required in reply to this Office action.										
12)	12) The oath or declaration is objected to by the Examiner.									
Priority ι	ınder 35 U.S.C. §§ 119 and 120									
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).										
a) All b) Some * c) None of:										
	1. Certified copies of the priority documents	ments have bee	n receive	d.						
	2. Certified copies of the priority documents have been received in Application No									
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.										
14) 🗌 🗸	14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).									
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.										
Attachment(s)										
2) Notice	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-94 mation Disclosure Statement(s) (PTO-1449) Paper N	18) 4o(s)	5) 🔲 No		(PTO-413) Paper Nation (P					

Art Unit: 1653

## **DETAILED ACTION**

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1, 4-7, 9 and 10, drawn to an isolated nucleic acid construct containing that nucleic acid and a recombinant method of using the construct where claims 7 and 10 are drawn to a process of making a polypeptide by recombinant means, classified in 435, subclass 69.1.
- II. Claims 2-3, drawn to an isolated polypeptide, classified in class 530, subclass350.
- III. Claim 8, drawn to a method of identifying an agent capable of modulating a nucleic acid molecule, classified in class 435, subclass 6.

The inventions are distinct, each from the other because of the following reasons:

Claims 2 and 3 of Invention II encompasses 2 distinct proteins with different primary structure. The proteins are structurally different; therefore, the applicant must elect a specific sequence for examination. If Invention II is elected, claims 2 and 3 will be examined only in-sofar as it pertains to the elected SEQ ID NO.

Claim 1 encompasses DNAs encoding 2 different proteins. The applicant must select a specific sequence for examination.

Art Unit: 1653

Applicant is advised that a reply to this requirement must include an identification of the peptide or nucleic acid that is elected consonant with this requirement, and a listing of all claims readable thereon, including and claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

This election requirement is not to be construed as a species election, as these compounds do not share a common primary structure and appear to be patentably distinct.

Should applicant traverse on the ground that these different compounds are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the protein can be obtained by either the purification from a natural source or by chemical synthesis.

Inventions I and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product

Art Unit: 1653

as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case nucleic acids may be used as claimed in a method of making a polypeptide.

Inventions II and III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are unrelated because the peptides of Invention III are not used in the process of Invention III and are not products thereof.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, recognized divergent subject matter and because the searches required for each Group is not required for another, restriction for examination purposes as indicated is proper.

A telephone call was made to Clare M Iery on 24 Jan 2003 to request an oral election to the above restriction requirement, but did not result in an election being made.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Laurie Mayes whose telephone number is (703) 605-1208. The examiner can normally be reached on Monday through Friday from 7 AM to 3:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low can be reached on (703) 305-2923. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 305-3014 for regular communications and (703) 305-3014 for After Final communications.

Art Unit: 1653

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1123.

Laurie Mayes
Patent Examiner
Art Unit 1653

January 14, 2003

Christopher & De hu

CHRISTOPHER S. F. LOW SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600